MedTrace Logo

Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia

NCT04106076 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2020-07-14

No results posted yet for this study

Summary

This is a Phase I, open-label, dose escalation study of UCART123 administered intravenously to patients with newly diagnosed CD123 positive adverse genetic risk acute myeloid leukaemia (AML) defined in the ELN adverse genetic risk group (2017). The purpose of this study is to evaluate the safety and clinical activity of multiple infusions of UCART123 and to determine the Maximum Tolerated Dose (MTD).

Conditions

  • Acute Myeloid Leukaemia

Interventions

BIOLOGICAL

UCART123

Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor

Sponsors & Collaborators

  • Cellectis S.A.

    lead INDUSTRY

Principal Investigators

  • Ghulam Mufti, Pr · Kings college London NHS Foundation Trust

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-11
Primary Completion
2019-12-05
Completion
2019-12-05

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04106076 on ClinicalTrials.gov